Ni Ming-Jie, Jin Yu-Ting, Wu Qian-Lin, Zhang Ning, Tian Jia-He, Li Jun, Yuan Kai-Ming
Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Key Laboratory of Pediatric Anesthesiology, Ministry of Education, Wenzhou Medical University, Key Laboratory of Anesthesiology of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Anesthesiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Front Pharmacol. 2024 Mar 20;15:1372139. doi: 10.3389/fphar.2024.1372139. eCollection 2024.
Most preschool children are distressed during anesthesia induction. While current pharmacological methods are useful, there is a need for further optimization to an "ideal" standard. Remimazolam is an ultra-short-acting benzodiazepine, and intranasal remimazolam for pre-induction sedation may be promising.
This study included 32 preschool children who underwent short and minor surgery between October 2022 and January 2023. After pretreatment with lidocaine, remimazolam was administered to both nostrils using a mucosal atomizer device. The University of Michigan Sedation Score (UMSS) was assessed for sedation 6, 9, 12, 15, and 20 min after intranasal atomization. We used Dixon's up-and-down method, and probit and isotonic regressions to determine the 50% effective dose (ED) and 95% effective dose (ED) of intranasal remimazolam for pre-induction sedation. Results: Twenty-nine pediatric patients were included in the final analysis. The ED and ED of intranasal remimazolam for successful pre-induction sedation, when processed via probit analysis, were 0.65 (95% confidence interval [CI], 0.59-0.71) and 0.78 mg/kg (95% CI, 0.72-1.07), respectively. In contrast, when processed by isotonic regression, they were 0.65 (95% CI: 0.58-0.72 mg/kg) and 0.78 mg/kg (95% CI: 0.69-1.08 mg/kg), respectively. At 6 min after intranasal remimazolam treatment, 81.2% (13/16) of "positive" participants were successfully sedated with a UMSS ≧ 1. All the "positive" participants were successfully sedated within 9 min.
Intranasal remimazolam is feasible for preschool children with a short onset time. For successful pre-induction sedation, the ED and ED of intranasal remimazolam were 0.65 and 0.78 mg/kg, respectively.
大多数学龄前儿童在麻醉诱导期间会感到痛苦。虽然目前的药理学方法很有用,但仍需要进一步优化至“理想”标准。瑞马唑仑是一种超短效苯二氮䓬类药物,鼻内给予瑞马唑仑用于诱导前镇静可能很有前景。
本研究纳入了2022年10月至2023年1月期间接受短小手术的32名学龄前儿童。在利多卡因预处理后,使用黏膜雾化装置向双侧鼻孔给予瑞马唑仑。在鼻内雾化后6、9、12、15和20分钟评估密歇根大学镇静评分(UMSS)以评估镇静效果。我们使用狄克逊上下法、概率分析和等渗回归来确定鼻内给予瑞马唑仑用于诱导前镇静的50%有效剂量(ED)和95%有效剂量(ED)。结果:29名儿科患者纳入最终分析。通过概率分析处理时,鼻内瑞马唑仑成功诱导前镇静的ED和ED分别为0.65(95%置信区间[CI],0.59 - 0.71)和0.78mg/kg(95%CI,0.72 - 1.07)。相比之下,通过等渗回归处理时,它们分别为0.65(95%CI:0.58 - 0.72mg/kg)和0.78mg/kg(95%CI:0.69 - 1.08mg/kg)。在鼻内给予瑞马唑仑治疗后6分钟,81.2%(13/16)的“阳性”参与者通过UMSS≧1成功镇静。所有“阳性”参与者在9分钟内成功镇静。
鼻内给予瑞马唑仑对学龄前儿童是可行的且起效时间短。对于成功诱导前镇静,鼻内瑞马唑仑的ED和ED分别为0.65和0.78mg/kg。